论文部分内容阅读
观察丝裂霉素（ＭＭＣ）、长春花碱酰胺（ＶＤＳ）与顺铂（ＰＤＤ）组成的 ＭＶＰ方案治疗非小细胞肺癌的疗效及副作 用。［方法］４２例晚期非小细胞肺癌患者接受ＭＶＰ方案治疗，每例至少２个周期，按ＷＨＯ疗效及毒性标准进行评价。［结果］ＭＶＰ 方案对非小细胞肺癌的有效率为４２．９％，主要毒性反应为骨髓抑制，其次为脱发及周围神经炎，其他系统毒性均较轻。［结论］ ＭＶＰ方案对非小细胞肺癌疗效较高，毒性反应较轻，可以作为治疗非小细胞肺癌的一线方案。
To observe the efficacy and side effects of MVP regimen composed of mitomycin C (MMC), vinblastine amide (VDS) and cisplatin (PDD) in the treatment of non-small cell lung cancer. [Methods] Forty-two patients with advanced non-small cell lung cancer received MVP regimen. At least 2 cycles per case were evaluated according to WHO efficacy and toxicity criteria. [Results] The effective rate of MVP regimen for non-small cell lung cancer was 42.9%. The main toxicity was bone marrow suppression, followed by hair loss and peripheral neuritis. The other systemic toxicity was mild. [Conclusion] The MVP regimen has a higher curative effect on non-small cell lung cancer with less toxicity. It can be used as the first-line treatment for non-small cell lung cancer.